Indonesia, Malaysia, Philippines, Thailand and Vietnam IgA Nephropathy Market

Description

List of Tables

The Indonesia, Malaysia, Thailand, Phillipnes, and Vietnam IgA nephropathy market is expected to reach USD 42,340.41 thousand by 2034 from USD 15,716.44 thousand in 2023, growing with a CAGR of 10.1% in the forecast period of 2024 to 2034.

Market Segmentation

Indonesia, Malaysia, Thailand, Philippines and Vietnam IgA Nephropathy Market, By Disease Type (Primary IgA Nephropathy and Secondary IgA Nephropathy), Type (Diagnosis and Treatment), Population Type (Adults, Geriatric, and Pediatric), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Specialty Clinics, Diagnostic Centers, Ambulatory Care Centers, Home Healthcare, and Others), Distribution Channel (Retail Sales, Direct Tenders, and Others), Country (Indonesia, Malaysia, Thailand, Philippines, and Vietnam) - Industry Trends and Forecast to 2034.

Overview of Indonesia, Malaysia, Thailand, Philippines and Vietnam IgA Nephropathy Market Dynamics:

Driver
Rise in the number of IgA nephropathy cases
Restraint
High cost of IgA nephropathy treatment
Opportunity
Collaboration among market players for drug development

Market Players

Some of the major market players operating in the Indonesia, Malaysia, Thailand, Philippines and Vietnam IgA nephropathy market are:

Sun Pharmaceutical Industries Ltd
Pfizer Inc.
Zydus Group
Novartis AG
ARKRAY USA, Inc.
Teva Pharmaceutical USA Inc.

1 INTRODUCTION 17

1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 OVERVIEW OF INDONESIA, MALAYSIA, THAILAND, PHILIPPINES & VIETNAM IGA NEPHROPATHY MARKET 17
1.4 LIMITATIONS 19
1.5 MARKETS COVERED 20

2 MARKET SEGMENTATION 22

2.1 MARKETS COVERED 22
2.2 YEARS CONSIDERED FOR THE STUDY 23
2.3 CURRENCY AND PRICING 23
2.4 DBMR TRIPOD DATA VALIDATION MODEL 24
2.5 MULTIVARIATE MODELLING 27
2.6 DBMR MARKET POSITION GRID 29
2.7 VENDOR SHARE ANALYSIS 30
2.8 SECONDARY SOURCES 31
2.9 ASSUMPTIONS 31

3 EXECUTIVE SUMMARY 32

4 PREMIUM INSIGHT 34

4.1 PESTEL ANALYSIS 35
4.2 PORTER'S FIVE FORCES 36
4.3 PREVALENCE OF IGA NEPHROPATHY 37
4.4 INCIDENCE OF IGA NEPHROPATHY 37
4.5 CURRENT TREATMENT OF IGA NEPHROPATHY 37
4.6 EXPENDITURE OF IGA NEPHROPATHY 37
4.7 DETECTION METHODS OF IGA NEPHROPATHY 38

5 MARKET OVERVIEW 40

5.1 DRIVERS 42
- 5.1.1 RISE IN THE NUMBER OF CASES OF IGA NEPHROPATHY 42
- 5.1.2 INCREASE IN THE AVAILABILITY OF IGA-TARGETED PIPELINE DRUGS 42
- 5.1.3 INCREASING INVESTMENT IN R&D OF DRUG DISCOVERY 42
- 5.1.4 INCREASING PRODUCT APPROVALS FOR IGA NEPHROPATHY TREATMENT 43
5.2 RESTRAINTS 43
- 5.2.1 HIGH COST OF IGA NEPHROPATHY TREATMENT 43
- 5.2.2 DELAYED DIAGNOSIS OF IGA NEPHROPATHY 44
- 5.2.3 POOR PLANNING OF IGA NEPHROPATHY TREATMENT IN LOW-INCOME COUNTRIES 44
- 5.2.4 INABILITY TO EFFECTIVELY TREAT IGA NEPHROPATHY 44
5.3 OPPORTUNITIES 45
- 5.3.1 COLLABORATION AMONG MARKET PLAYERS FOR DRUG DEVELOPMENT 45
- 5.3.2 INCREASE IN GOVERNMENT FUNDING FOR RESEARCH PURPOSES 45
- 5.3.3 INCREASING TREND OF NOVEL DIAGNOSIS PROCEDURE 46
5.4 CHALLENGES 46
- 5.4.1 LOW AWARENESS AMONG THE POPULATION REGARDING KIDNEY DISEASE 46
- 5.4.2 STRINGENT GOVERNMENT REGULATIONS RELATED TO THE APPROVAL OF NEUROENDOCRINE TUMOR DRUG 47

6 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY DISEASE TYPE 48

6.1 OVERVIEW 49
6.2 PRIMARY IGA NEPHROPATHY 52
6.3 SECONDARY IGA NEPHROPATHY 52

7 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY TYPE 53

7.1 OVERVIEW 54
7.2 DIAGNOSIS 57
- 7.2.1 URINE TEST 57
  - 7.2.1.1 URINE ALBUMIN-TO-CREATININE RATIO 57
  - 7.2.1.2 DIPSTICK TEST FOR ALBUMIN AND BLOOD 58
- 7.2.2 BLOOD TEST 58
- 7.2.3 IOTHALAMATE CLEARANCE TEST 58
- 7.2.4 KIDNEY BIOPSY 58
- 7.2.5 OTHERS 58
7.3 TREATMENT 58
- 7.3.1 BLOOD PRESSURE LOWERING AGENTS 59
  - 7.3.1.1 ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 59
    - 7.3.1.1.1 LISINOPRIL 59
    - 7.3.1.1.2 ENALAPRIL 60
    - 7.3.1.1.3 RAMIPRIL 60
    - 7.3.1.1.4 BENAZEPRIL 60
    - 7.3.1.1.5 OTHERS 60
  - 7.3.1.2 ANGIOTENSIN RECEPTOR BLOCKERs 60
    - 7.3.1.2.1 LOSARTAN 60
    - 7.3.1.2.2 VALSARTAN 61
    - 7.3.1.2.3 IRBESARTAN 61
    - 7.3.1.2.4 OTHERS 61
- 7.3.2 IMMUNOSUPPRESANT 61
  - 7.3.2.1 CYCLOPHOSPHAMIDE 61
  - 7.3.2.2 AZATHIOPRINE 61
  - 7.3.2.3 CORTICOSTEROIDS 61
    - 7.3.2.3.1 METHYLPREDNISONE 62
    - 7.3.2.3.2 PREDNISOLONE 62
    - 7.3.2.3.3 OTHERS 62
  - 7.3.2.4 OTHERS 62
- 7.3.3 DIURETICS 63
  - 7.3.3.1 FUROSEMIDE 63
  - 7.3.3.2 TORSEMIDE 63
  - 7.3.3.3 BUMETANIDE 63
  - 7.3.3.4 OTHERS 63
- 7.3.4 BLOOD CHOLESTEROL LOWERING AGENTS 63
  - 7.3.4.1 ATROVASTATIN 64
  - 7.3.4.2 SIMVASTATIN 64
  - 7.3.4.3 ROSUVASTATIN 64
  - 7.3.4.4 FLUVASTATIN 64
  - 7.3.4.5 PRAVASTATIN 64
  - 7.3.4.6 OTHERS 64
- 7.3.5 SUPPLEMENTS 65
  - 7.3.5.1 OMEGA-3-FATTY ACIDS 65
  - 7.3.5.2 VITAMIN E 65
  - 7.3.5.3 OTHERS 65
- 7.3.6 OTHERS 65

8 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY POPULATION TYPE 66

8.1 OVERVIEW 67
8.2 ADULTS 70
8.3 GERIATRIC 70
8.4 PEDIATRIC 70

9 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION 71

9.1 OVERVIEW 72
9.2 ORAL 75
- 9.2.1 TABLETS/PILLS 75
- 9.2.2 CAPSULES 75
- 9.2.3 OTHERS 75
9.3 PARENTERAL 76
- 9.3.1 INTRAVENOUS 76
- 9.3.2 SUBCUTANEOUS 76
- 9.3.3 OTHERS 76
9.4 OTHERS 76

10 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY END USER 77

10.1 OVERVIEW 78
10.2 HOSPITALS 81
- 10.2.1 PRIVATE 81
- 10.2.2 PUBLIC 81
10.3 SPECIALTY CLINICS 81
10.4 DIAGNOSTIC CENTERS 81
10.5 AMBULATORY CARE CENTERS 81
10.6 HOME HEALTHCARE 82
10.7 OTHERS 82

11 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL 83

11.1 OVERVIEW 84
11.2 RETAIL SALES 87
- 11.2.1 HOSPITAL PHARMACY 87
- 11.2.2 ONLINE PHARMACY 87
- 11.2.3 RETAIL PHARMACY 87
11.3 DIRECT TENDER 87
11.4 OTHERS 87

12 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM 88

12.1 MALAYSIA 89
12.2 THAILAND 95
12.3 INDONESIA 101
12.4 PHILIPPINES 107
12.5 VIETNAM 113

13 INDONESIA, MALAYSIA, PHILIPPINES, VIETNAM, AND THAILAND IGA NEPHROPATHY MARKET, COMPANY LANDSCAPE 119

13.1 COMPANY SHARE ANALYSIS: INDONESIA, MALAYSIA, PHILIPPINES, VIETNAM, AND THAILAND 119

14 SWOT ANALYSIS 120

15 COMPANY PROFILE 121

15.1 SUN PHARMACEUTICAL INDUSTRIES LTD 121
- 15.1.1 COMPANY SNAPSHOT 121
- 15.1.2 REVENUE ANALYSIS 122
- 15.1.3 PRODUCT PORTFOLIO 122
- 15.1.4 RECENT DEVELOPMENTS 123
15.3 PFIZER INC. 124
- 15.3.1 COMPANY SNAPSHOT 124
- 15.3.2 REVENUE ANALYSIS 124
- 15.3.3 PRODUCT PORTFOLIO 125
- 15.3.4 RECENT DEVELOPMENT 125
15.4 ZYDUS GROUP. 126
- 15.4.1 COMPANY SNAPSHOT 126
- 15.4.2 REVENUE ANALYSIS 126
- 15.4.3 PRODUCT PORTFOLIO 127
- 15.4.4 RECENT DEVELOPMENTS 127
15.5 NOVARTIS AG 128
- 15.5.1 COMPANY SNAPSHOT 128
- 15.5.2 REVENUE ANALYSIS 128
- 15.5.3 PRODUCT PORTFOLIO 129
- 15.5.4 RECENT DEVELOPMENTS 129
15.6 ARKRAY USA, INC. 131
- 15.6.1 COMPANY SNAPSHOT 131
- 15.6.2 PRODUCT PORTFOLIO 131
- 15.6.3 RECENT DEVELOPMENTS 131
15.7 TEVA PHARMACEUTICAL USA INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.) 132
- 15.7.1 COMPANY SNAPSHOT 132
- 15.7.2 REVENUE FINANCIALS 132
- 15.7.3 PRODUCT PORTFOLIO 133
- 15.7.4 RECENT DEVELOPMENTS 133

16 QUESTIONNAIRE 135

17 RELATED REPORTS 138

LIST OF TABLES

TABLE 1 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2022-2034 (USD THOUSAND) 51
TABLE 2 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 56
TABLE 3 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 57
TABLE 4 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 57
TABLE 5 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 58
TABLE 6 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 59
TABLE 7 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 59
TABLE 8 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM ANGIOTENSIN RECEPTOR BLOCKERS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 60
TABLE 9 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IMMUNOSUPPRESSANT IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 61
TABLE 10 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 62
TABLE 11 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 63
TABLE 12 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM BLOOD CHOLESTEROL LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 64
TABLE 13 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 65
TABLE 14 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2022-2034 (USD THOUSAND) 69
TABLE 15 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND) 74
TABLE 16 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM ORAL IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND) 75
TABLE 17 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND) 76
TABLE 18 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY END USER, 2022-2034 (USD THOUSAND) 80
TABLE 19 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM HOSPITALS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 81
TABLE 20 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2022-2034 (USD THOUSAND) 86
TABLE 21 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM RETAIL SALES IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 87
TABLE 22 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY REGION, 2022-2034 (USD THOUSAND) 88
TABLE 23 MALAYSIA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2022-2034 (USD THOUSAND) 89
TABLE 24 MALAYSIA IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 89
TABLE 25 MALAYSIA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 89
TABLE 26 MALAYSIA URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 89
TABLE 27 MALAYSIA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 90
TABLE 28 MALAYSIA BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 90
TABLE 29 MALAYSIA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 90
TABLE 30 MALAYSIA ANGIOTENSIN RECEPTOR BLOCKERS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 91
TABLE 31 MALAYSIA IMMUNOSUPPRESSANT IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 91
TABLE 32 MALAYSIA CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 91
TABLE 33 MALAYSIA DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 91
TABLE 34 MALAYSIA BLOOD CHOLESTEROL LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 92
TABLE 35 MALAYSIA SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 92
TABLE 36 MALAYSIA IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2022-2034 (USD THOUSAND) 92
TABLE 37 MALAYSIA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND) 92
TABLE 38 MALAYSIA ORAL IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND) 93
TABLE 39 MALAYSIA PARENTERAL IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND) 93
TABLE 40 MALAYSIA IGA NEPHROPATHY MARKET, BY END USER, 2022-2034 (USD THOUSAND) 93
TABLE 41 MALAYSIA HOSPITALS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 93
TABLE 42 MALAYSIA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2022-2034 (USD THOUSAND) 94
TABLE 43 MALAYSIA RETAIL SALES IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 94
TABLE 44 THAILAND IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2022-2034 (USD THOUSAND) 95
TABLE 45 THAILAND IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 95
TABLE 46 THAILAND DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 95
TABLE 47 THAILAND URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 95
TABLE 48 THAILAND TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 96
TABLE 49 THAILAND BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 96
TABLE 50 THAILAND ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 96
TABLE 51 THAILAND ANGIOTENSIN RECEPTOR BLOCKERS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 97
TABLE 52 THAILAND IMMUNOSUPPRESSANT IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 97
TABLE 53 THAILAND CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 97
TABLE 54 THAILAND DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 97
TABLE 55 THAILAND BLOOD CHOLESTEROL LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 98
TABLE 56 THAILAND SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 98
TABLE 57 THAILAND IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2022-2034 (USD THOUSAND) 98
TABLE 58 THAILAND IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND) 98
TABLE 59 THAILAND ORAL IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND) 99
TABLE 60 THAILAND PARENTERAL IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND) 99
TABLE 61 THAILAND IGA NEPHROPATHY MARKET, BY END USER, 2022-2034 (USD THOUSAND) 99
TABLE 62 THAILAND HOSPITALS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 99
TABLE 63 THAILAND IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2022-2034 (USD THOUSAND) 100
TABLE 64 THAILAND RETAIL SALES IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 100
TABLE 65 INDONESIA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2022-2034 (USD THOUSAND) 101
TABLE 66 INDONESIA IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 101
TABLE 67 INDONESIA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 101
TABLE 68 INDONESIA URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 101
TABLE 69 INDONESIA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 102
TABLE 70 INDONESIA BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 102
TABLE 71 INDONESIA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 102
TABLE 72 INDONESIA ANGIOTENSIN RECEPTOR BLOCKERS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 103
TABLE 73 INDONESIA IMMUNOSUPPRESSANT IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 103
TABLE 74 INDONESIA CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 103
TABLE 75 INDONESIA DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 104
TABLE 76 INDONESIA BLOOD CHOLESTEROL LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 104
TABLE 77 INDONESIA SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 104
TABLE 78 INDONESIA IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2022-2034 (USD THOUSAND) 105
TABLE 79 INDONESIA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND) 105
TABLE 80 INDONESIA ORAL IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND) 105
TABLE 81 INDONESIA PARENTERAL IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND) 105
TABLE 82 INDONESIA IGA NEPHROPATHY MARKET, BY END USER, 2022-2034 (USD THOUSAND) 106
TABLE 83 INDONESIA HOSPITALS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 106
TABLE 84 INDONESIA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2022-2034 (USD THOUSAND) 106
TABLE 85 INDONESIA RETAIL SALES IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 106
TABLE 86 PHILIPPINES IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2022-2034 (USD THOUSAND) 107
TABLE 87 PHILIPPINES IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 107
TABLE 88 PHILIPPINES DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 107
TABLE 89 PHILIPPINES URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 107
TABLE 90 PHILIPPINES TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 108
TABLE 91 PHILIPPINES BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 108
TABLE 92 PHILIPPINES ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 108
TABLE 93 PHILIPPINES ANGIOTENSIN RECEPTOR BLOCKERS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 109
TABLE 94 PHILIPPINES IMMUNOSUPPRESSANT IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 109
TABLE 95 PHILIPPINES CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 109
TABLE 96 PHILIPPINES DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 109
TABLE 97 PHILIPPINES BLOOD CHOLESTEROL LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 110
TABLE 98 PHILIPPINES SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 110
TABLE 99 PHILIPPINES IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2022-2034 (USD THOUSAND) 110
TABLE 100 PHILIPPINES IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND) 110
TABLE 101 PHILIPPINES ORAL IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND) 111
TABLE 102 PHILIPPINES PARENTERAL IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND) 111
TABLE 103 PHILIPPINES IGA NEPHROPATHY MARKET, BY END USER, 2022-2034 (USD THOUSAND) 111
TABLE 104 PHILIPPINES HOSPITALS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 111
TABLE 105 PHILIPPINES IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2022-2034 (USD THOUSAND) 112
TABLE 106 PHILIPPINES RETAIL SALES IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 112
TABLE 107 VIETNAM IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2022-2034 (USD THOUSAND) 113
TABLE 108 VIETNAM IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 113
TABLE 109 VIETNAM DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 113
TABLE 110 VIETNAM URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 113
TABLE 111 VIETNAM TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 114
TABLE 112 VIETNAM BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 114
TABLE 113 VIETNAM ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 114
TABLE 114 VIETNAM ANGIOTENSIN RECEPTOR BLOCKERS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 115
TABLE 115 VIETNAM IMMUNOSUPPRESSANT IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 115
TABLE 116 VIETNAM CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 115
TABLE 117 VIETNAM DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 115
TABLE 118 VIETNAM BLOOD CHOLESTEROL LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 116
TABLE 119 VIETNAM SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 116
TABLE 120 VIETNAM IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2022-2034 (USD THOUSAND) 116
TABLE 121 VIETNAM IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND) 117
TABLE 122 VIETNAM ORAL IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND) 117
TABLE 123 VIETNAM PARENTERAL IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2034 (USD THOUSAND) 117
TABLE 124 VIETNAM IGA NEPHROPATHY MARKET, BY END USER, 2022-2034 (USD THOUSAND) 117
TABLE 125 VIETNAM HOSPITALS IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 118
TABLE 126 VIETNAM IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2022-2034 (USD THOUSAND) 118
TABLE 127 VIETNAM RETAIL SALES IN IGA NEPHROPATHY MARKET, BY TYPE, 2022-2034 (USD THOUSAND) 118

LIST OF FIGURES

FIGURE 1 INDONESIA, MALAYSIA, THAILAND, PHILIPPINES, AND VIETNAM IGA NEPHROPATHY MARKET: SEGMENTATION 22
FIGURE 2 INDONESIA, MALAYSIA, THAILAND, PHILIPPINES, AND VIETNAM IGA NEPHROPATHY MARKET: DATA TRIANGULATION 24
FIGURE 3 INDONESIA, MALAYSIA, THAILAND, PHILIPPINES, AND VIETNAM IGA NEPHROPATHY MARKET: DROC ANALYSIS 25
FIGURE 4 INDONESIA, MALAYSIA, THAILAND, PHILIPPINES, AND VIETNAM IGA NEPHROPATHY MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 26
FIGURE 5 INDONESIA, MALAYSIA, THAILAND, PHILIPPINES, AND VIETNAM IGA NEPHROPATHY MARKET: COMPANY RESEARCH ANALYSIS 26
FIGURE 6 INDONESIA, MALAYSIA, THAILAND, PHILIPPINES, AND VIETNAM IGA NEPHROPATHY MARKET: MULTIVARIATE MODELLING 27
FIGURE 7 INDONESIA, MALAYSIA, THAILAND, PHILIPPINES, AND VIETNAM IGA NEPHROPATHY MARKET: DBMR MARKET POSITION GRID 29
FIGURE 8 INDONESIA, MALAYSIA, THAILAND, PHILIPPINES, AND VIETNAM IGA NEPHROPATHY MARKET: VENDOR SHARE ANALYSIS 30
FIGURE 9 INDONESIA, MALAYSIA, THAILAND, PHILIPPINES, AND VIETNAM IGA NEPHROPATHY MARKET: SEGMENTATION 33
FIGURE 10 RISE IN IGA NEPHROPATHY DISORDER IS DRIVING THE INDONESIA, MALAYSIA, THAILAND, PHILIPPINES, AND VIETNAM, IGA NEPHROPATHY MARKET IN THE FORECAST PERIOD OF 2024 TO 2034 34
FIGURE 11 PRIMARY IGA NEPHROPATHY IS EXPECTED TO ACCOUNT FOR LARGEST SHARE IN THE TYPE SEGEMENT 34
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET 41
FIGURE 13 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET: BY DISEASE TYPE, 2023 49
FIGURE 14 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET: BY DISEASE TYPE, 2024-2034 (USD THOUSAND) 50
FIGURE 15 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET: BY DISEASE TYPE, CAGR (2024-2031) 50
FIGURE 16 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET: BY DISEASE TYPE, LIFELINE CURVE 51
FIGURE 17 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET: BY TYPE, 2023 54
FIGURE 18 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET: BY TYPE, 2023-2034 (USD THOUSAND) 55
FIGURE 19 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET: BY TYPE, CAGR (2023-2034) 55
FIGURE 20 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET: BY TYPE, LIFELINE CURVE 56
FIGURE 21 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET: BY POPULATION TYPE, 2023 67
FIGURE 22 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET: BY POPULATION TYPE, 2024-2034 (USD THOUSAND) 68
FIGURE 23 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET: BY POPULATION TYPE, CAGR (2024-2034) 68
FIGURE 24 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET: BY POPULATION TYPE, LIFELINE CURVE 69
FIGURE 25 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET: BY ROUTE OF ADMINISTRATION, 2023 72
FIGURE 26 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET: BY ROUTE OFADMINISTRATION, 2024-2034 (USD THOUSAND) 73
FIGURE 27 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2034) 73
FIGURE 28 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 74
FIGURE 29 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET: BY END USER, 2023 78
FIGURE 30 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET: BY END USER, 2024-2034 (USD THOUSAND) 79
FIGURE 31 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET: BY END USER, CAGR (2024-2034) 79
FIGURE 32 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET: BY END USER, LIFELINE CURVE 80
FIGURE 33 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET: BY DISTRIBUTION CHANNEL, 2023 84
FIGURE 34 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET: BY DISTRIBUTION CHANNEL, 2024-2034 (USD THOUSAND) 85
FIGURE 35 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2034) 85
FIGURE 36 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 86
FIGURE 37 INDONESIA, MALAYSIA, PHILIPPINES, VIETNAM AND THAILAND IGA NEPHROPATHY MARKET: COMPANY SHARE 2023 (%) 119

Indonesia, Malaysia, Philippines, Thailand and Vietnam IgA Nephropathy Market - Industry Trends and Forecast to 2031